IceCure Medical's ProSense System Approved in Switzerland
Ticker: ICCM · Form: 6-K · Filed: Nov 18, 2025 · CIK: 1584371
Sentiment: bullish
Topics: regulatory-approval, medical-device, europe
TL;DR
IceCure Medical's ProSense system just got approved in Switzerland for multiple cancer types. Big win for European expansion!
AI Summary
On November 18, 2025, IceCure Medical Ltd. announced that its ProSense® Cryoablation System received regulatory approval in Switzerland. This approval covers indications for treating breast, lung, liver, and kidney cancer, expanding the system's market reach in Europe.
Why It Matters
This Swiss regulatory approval signifies a significant step for IceCure Medical in expanding its European market presence for cancer treatment solutions.
Risk Assessment
Risk Level: low — The filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and subject of the press release.
- ProSense® Cryoablation System (company) — The medical device that received regulatory approval.
- Switzerland (company) — Country where regulatory approval was granted.
FAQ
What specific indications were approved for the ProSense® Cryoablation System in Switzerland?
The ProSense® Cryoablation System received regulatory approval in Switzerland for indications including breast, lung, liver, and kidney cancer.
What is the filing number for IceCure Medical Ltd.'s report?
The SEC file number for IceCure Medical Ltd. is 001-40753.
When was the press release regarding the Swiss approval issued?
The press release was issued on November 18, 2025.
What type of report is this filing?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Where is IceCure Medical Ltd.'s principal executive office located?
IceCure Medical Ltd.'s principal executive office is located at 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2025-11-18 08:45:43
Filing Documents
- ea0266067-6k_icecure.htm (6-K) — 12KB
- ea026606701ex99-1_icecure.htm (EX-99.1) — 11KB
- 0001213900-25-111793.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: November 18, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 3